IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025

 Aggregated presentation by day and by market

              Statement of transactions in own shares from June 16th to June 20th 2025

Name of the issuerIdentity code of the issuer

(Legal Entity Identifier) 		Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket

(MIC Code) 		 
IPSEN549300M6SGDPB4Z94P1116/06/2025FR0010259150   140   103,60AQEU
IPSEN549300M6SGDPB4Z94P1116/06/2025FR0010259150   221   103,50CCXE
IPSEN549300M6SGDPB4Z94P1116/06/2025FR0010259150   500   103,55TQEX
IPSEN549300M6SGDPB4Z94P1116/06/2025FR0010259150  3 719   103,48669XPAR
IPSEN549300M6SGDPB4Z94P1117/06/2025FR0010259150   519   102,96647AQEU
IPSEN549300M6SGDPB4Z94P1117/06/2025FR0010259150  1 500   102,99827CCXE
IPSEN549300M6SGDPB4Z94P1117/06/2025FR0010259150   434   102,95069TQEX
IPSEN549300M6SGDPB4Z94P1117/06/2025FR0010259150  3 842   103,05877XPAR
IPSEN549300M6SGDPB4Z94P1118/06/2025FR0010259150   400   101,70AQEU
IPSEN549300M6SGDPB4Z94P1118/06/2025FR0010259150  1 300   101,78462CCXE
IPSEN549300M6SGDPB4Z94P1118/06/2025FR0010259150   500   101,74TQEX
IPSEN549300M6SGDPB4Z94P1118/06/2025FR0010259150  5 079   101,71372XPAR
IPSEN549300M6SGDPB4Z94P1119/06/2025FR0010259150  3 894   101,11746XPAR
IPSEN549300M6SGDPB4Z94P1120/06/2025FR0010259150  8 042   101,46176XPAR
   TOTAL30 090 102,1193 

Attachment



EN
24/06/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

February 27, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

February 27, 2026 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch